Publication number: 20080193457
Abstract: The present invention provides novel naturally-processed MHC class II antigenic peptides; which originate from interferon-?-inducible lysosomal thiol reductase, integrin beta-2, phosphatitylinositol-4,5-bisphosphate 3-kinase, urokinase-type plas-minogen activator, immunoglobulin heavy chain V-III region (VH26), DJ-1 protein, apolipoprotein B-100, 26S proteasome non-AT-Pase regulatory subunit 8, interleukin-1 receptor, fibromodulin, GM-CSF/IL-3/IL-5 receptor, sorting nexin 3, inter-?-trypsin inhibitor heavy chain H4, complement C4, complement C3 (?-chain), complement C3 (?-chain), SH3 domain-binding glutamic acid-rich-like protein 3, interleukin-4-induced protein 1, hemopexin, Hsc70-interacting protein, invariant chain (Ii), retinoic acid receptor responder protein 2, fibronectin, cathepsin B, tripeptidyl-peptidase II, legumain, platelet activating factor receptor, poly-alpha-2.8-sialyltrans-ferase, and ras-leated protein Rab-11B.
Type:
Application
Filed:
July 30, 2004
Publication date:
August 14, 2008
Inventors:
Nikolaos Berntenis, Gerrit Buurman, Harald Kropshofer, Bernd Christian Mueller, Sebastian Thomas Spindeldreher, Anne Vogt, Werner Zolg